Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

roval decisions for new drug applications by health authorities is an uncertain and evolving process and health authorities retain significant discretion at all stages of the regulatory review and approval decision process; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) the outcome of any existing or future intellectual property or other litigation related to our drug candidates and those of our collaboration partners.  Other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2014. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.  Nektar Investor Inquiries: Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:
Jodi Sievers/Nektar Therapeutics(415) 482-5593 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSJune 30, 2014Dece
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering  of 40,229,886 units. Each unit consists of one ... warrant to purchase one share of common stock, and ... share of common stock, at a purchase price of ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
(Date:6/30/2015)... ... June 30, 2015 , ... After many requests from international ... here, http://www.express-glasses.com is proud to announce its collaboration with DHL for ... with DHL Express when calling or visiting the express glasses website. express glasses ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... currently pending in a federal multidistrict litigation now underway in the U.S. District ... next monthly Status Conference. According to the Court’s calendar, that conference has now ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Rocky Mountain ... has restructured its management team and added a new CEO, Mr. Darold Francis. The ... leading selection of premium essential oils that customers have come to know and respect ...
(Date:6/30/2015)... ... June 30, 2015 , ... Allied Anesthesia physicians are ... division volunteered to help provide free outpatient procedures to some of Orange County’s ... Jude Medical Center. , The event was coordinated by AccessOC, which was ...
(Date:6/30/2015)... ... 30, 2015 , ... MJH Associates today welcomed ... Research & Analytics , a consultative healthcare market research practice that is part ... HRA offers quantitative and qualitative, custom and multi-client primary market research services to ...
Breaking Medicine News(10 mins):Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3
... , , SOUTH SAN ... PARD ), a biopharmaceutical company focused on innovative oncology ... executive officer, is scheduled to provide a corporate overview, including ... lead product candidate, picoplatin, at two upcoming investor conferences: , ...
... day cut risk in half in study of Finnish men ... associated with moderate- to high-intensity exercise appears to reduce the ... Finnish study included 2,560 men, aged 42 to 61, whose ... the men had a history of cancer, according to the ...
... CDC recommendations loom, new study confirms this group at great ... officials meet Wednesday to decide who should get priority for ... the virus poses to pregnant women should vault that group ... panel convened by the U.S. Centers for Disease Control and ...
... DARIEN, Conn., July 29 Now served in over 4000 schools across ... is expanding its availability into the retail sector. In addition to ... retailers Tops, D,Agostinos, Big Y, Kings and select Whole Foods ... keeps growing with Wegmans, Price Chopper and Kroger,s Eastern divisions all putting ...
... , , , ... EDI Health Group, Inc., (EHG), a provider of enhanced connectivity, ... in the dental industry, today announced significant additions to its ... during which the company implemented its industry-leading EDI (electronic data ...
... , , JACKSONVILLE, Fla., ... of Representatives for passing a bill (H.R. 3155) that will ... but endorsed a Senate bill (S. 801) that would provide ... caregivers who are in dire need of these services. H.R. ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2Health News:Prioritize Pregnant Women to Get Swine Flu Shot, Experts Say 2Health News:Prioritize Pregnant Women to Get Swine Flu Shot, Experts Say 3Health News:Prioritize Pregnant Women to Get Swine Flu Shot, Experts Say 4Health News:People Across the Country are Making The Switch! 2Health News:EDI Health Group Continues to Drive Growth of EDI Processing Services in the Dental Healthcare Industry Through Addition of 25 New Connections in the First Half of 2009 2Health News:EDI Health Group Continues to Drive Growth of EDI Processing Services in the Dental Healthcare Industry Through Addition of 25 New Connections in the First Half of 2009 3Health News:EDI Health Group Continues to Drive Growth of EDI Processing Services in the Dental Healthcare Industry Through Addition of 25 New Connections in the First Half of 2009 4Health News:Wounded Warrior Project (WWP) Pushes for Senate Bill to Assist Family Caregivers of the Most Severely Injured Veterans 2
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... area contact between grant material and fracture ... long bones., ,Grid-Like Format of Mesh Cathode ... Bone , ,The innovative Mesh Cathode of ... area and a scaffolding effect designed to ...
... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
... The PK Plasma-CISE™ (wire electrodes) ... single use devices that produce ... minimal thermal spread and Vapor ... superior hemostasis. The devices provide ...
Medicine Products: